Type a ticker — we pressure-test it against live facts, filings, and sentiment.
Intellia Therapeutics, Inc. — Healthcare · Biotechnology carries a Plainview business-quality score of 3.8/10, built deterministically from SEC filings and Yahoo Finance: revenue, margins, cash, valuation, and a confluence buy zone. The live X-Ray loads below.
On the fundamentals, Intellia Therapeutics, Inc. shows trailing revenue of $59.5M, net cash of $628.4M, a loss per share of -3.22, valued at about 28.6x times sales. X-Ray measures business quality only — momentum and entry timing live in Decide and Opportunity Cost.